In February 2025, the Decision Forum for the "New Methods" framework made a favorable coverage decision for transcutaneous vagus nerve stimulation (gammaCore) in the treatment of cluster headaches.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Buccheri et al. explored the challenges of conducting randomized controlled trials (RCTs) for high-risk medical devices, emphasizing the added complexities of intervention costs, patient randomization, and blinding processes. Drawing on experience from the CORE-MD project and large-scale pharmaceutical trials during the COVID-19 pandemic, the authors highlighted the potential of large simple RCTs for high-risk medical devices. These trials leverage routine healthcare data to improve efficiency, reduce costs, and accelerate patient recruitment while maintaining robust clinical evidence.

On January 30, 2025, the Institute for the Hospital Remuneration System (InEK) published the list of requests for innovation funding (NUB) submitted by hospitals in 2024. The medical technologies of cardiovascular, endoscopy, extracorporeal, gastrointestinal, neuromodulation, peripheral vascular, and other technology groups obtained positive status 1.

MTRC developed a White Paper exploring how value dossiers support payer negotiations, evidence synthesis, and strategic value communication in the MedTech sector. In this White Paper, we outline best practices for structuring value dossiers, tailoring messaging for different stakeholders, and leveraging them as a central evidence repository.

On January 24, 2025, the European Commission adopted an implementing regulation establishing the rules for joint scientific consultations on medical devices and in vitro diagnostic medical devices under the EU HTAR framework.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-based Publications Digest. In a recent publication, Messori et al. analyzed an algorithm for identifying innovative, high-risk medical devices in Tuscany, Italy. Due to its limitations ‒ such as a narrow selection of qualifying devices and reliance on strict objective criteria ‒ the authors introduced a "potentially innovative" category to accommodate devices with clinical and economic value. Based on an analysis of 17 devices, this refined classification supports a structured procurement approach, with plans for regional implementation in hospitals in the coming months.

On January 30, 2025, NHS England published a proposed 2025/26 NHS Payment Scheme (NHSPS) and launched a consultation. The scheme will be set for one financial year (starting on April 1, 2025). No significant changes were made to the general payment model. The changes include the introduction of tariffs for activities from Community Diagnostic Centres and a new Best Practice Tariff to incentivize shifting suitable procedures from day case or elective settings to outpatient settings. The deadline for comments submission is February 28, 2025.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 10th of February, we plan to work on 14 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Morris et al. conducted a scoping review of data on waste and greenhouse gas emissions in ophthalmic surgery. Results of 10 studies revealed that most emissions are linked to the procurement of surgical materials, followed by travel emissions and building energy. The authors also proposed a standardized waste-lifecycle framework to organize future research to help generate robust evidence for implementing impactful waste reduction strategies in ophthalmology.

On January 24, 2025, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for projects on new forms of care (for single-stage process – open topic and for two-stage process – nine topics).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Tornvall et al. conducted a systematic review of 12 economic evaluations of mHealth interventions for type 2 diabetes management. Most solutions ‒ featuring smartphone applications with text messaging and connected medical devices ‒ were generally deemed cost-effective or cost-saving. However, the authors highlighted moderate reporting quality, with a median CHEERS score of 59%. Methodological heterogeneity in outcome reporting further limits the overall robustness and comparability of the evidence for decision-makers.

In January 2025, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedures Guidance (Transperineal laser ablation for lower urinary tract symptoms of benign prostatic hyperplasia, electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder) and one new Early Value Assessment (Artificial intelligence technologies to help detect fractures on X-rays in urgent care). Furthermore, one new clinical guideline was published, and one was updated.